Kurzfassung

A Phase 3 Randomized, Double-Blind, Multicenter, Global Study of
Monalizumab or Placebo in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor